<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004254</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-08992</org_study_id>
    <secondary_id>EORTC-08992</secondary_id>
    <nct_id>NCT00004254</nct_id>
  </id_info>
  <brief_title>Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed</brief_title>
  <official_title>Phase II Study on Tomusex in Malignant Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of raltitrexed in treating patients who&#xD;
      have malignant mesothelioma that cannot be surgically removed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the therapeutic activity and toxicities of raltitrexed in patients&#xD;
      with inoperable malignant mesothelioma. II. Determine the objective response rate and&#xD;
      duration of response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Within 2 weeks of staging procedures, patients receive&#xD;
      raltitrexed IV over 15 minutes on day 1. Treatment repeats every 3 weeks for a maximum of 8&#xD;
      courses in the absence of disease progression or unacceptable toxicity. Patients are followed&#xD;
      every 6 weeks until disease progression and then every 8 weeks thereafter for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1999</start_date>
  <primary_completion_date type="Actual">June 2001</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">25</enrollment>
  <condition>Malignant Mesothelioma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltitrexed</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven inoperable malignant mesothelioma All tumor&#xD;
        stages eligible At least 1 target lesion with measurable disease in at least 1 dimension&#xD;
        (20 cm or more with conventional techniques OR 10 cm or more with spiral CT scans) Outside&#xD;
        irradiated field Prior surgery allowed if evidence of disease progression thereafter No&#xD;
        signs or symptoms of CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: ZUBROD/ECOG/WHO 0-2 (after&#xD;
        palliative measures such as pleural drainage) Life expectancy: Not specified Hematopoietic:&#xD;
        Hemoglobin at least 10.0 g/dL WBC at least 4,000/mm3 Absolute neutrophil count at least&#xD;
        2,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin less than 1.46 mg/dL&#xD;
        Albumin at least 3.0 g/dL ALT and AST less than 2.5 times upper limit of normal (ULN) (less&#xD;
        than 5 times ULN if liver involvement) Renal: Creatinine less than 1.69 mg/dL Creatinine&#xD;
        clearance at least 65 mL/min Other: No other malignancies (including melanoma,&#xD;
        hypernephroma, or breast carcinoma) within the past 5 years except basal cell or squamous&#xD;
        cell skin cancer or carcinoma in situ of the cervix Not pregnant or nursing Fertile&#xD;
        patients must use effective contraception No uncontrolled infection No psychologic,&#xD;
        familial, sociologic, or geographic condition that could interfere with compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent anticancer immunotherapy before&#xD;
        first disease progression Chemotherapy: No prior systemic or intracavitary cytotoxic drugs&#xD;
        No concurrent intrapleural or other systemic cytotoxic drugs Endocrine therapy: No&#xD;
        concurrent anticancer hormonal agents (except corticosteroids) before first disease&#xD;
        progression Radiotherapy: See Disease Characteristics Concurrent palliative radiotherapy&#xD;
        allowed for painful lesions, needle tracts, or surgical scars or prevention of metastases&#xD;
        along biopsy tracks At least 4 weeks since prior radiotherapy No prior radiotherapy to sole&#xD;
        indicator lesion unless lesion is clearly progressive Surgery: See Disease Characteristics&#xD;
        Prior pleurodesis allowed except with cytotoxic drugs (e.g., bleomycin) Concurrent&#xD;
        pleurodesis with noncytotoxic drugs allowed Other: At least 1 month since other prior&#xD;
        investigational agent No other concurrent anticancer agents before first disease&#xD;
        progression&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Giaccone, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Free University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale Bellaria</name>
      <address>
        <city>Bologna</city>
        <zip>I-40139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale per la Ricerca sul Cancro</name>
      <address>
        <city>Genoa</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita Degli Studi di Udine</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoekhuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1117 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Francart J, Legrand C, Sylvester R, Van Glabbeke M, van Meerbeeck JP, Robert A. Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group. J Clin Oncol. 2006 Jul 1;24(19):3007-12. doi: 10.1200/JCO.2005.05.1359.</citation>
    <PMID>16809726</PMID>
  </reference>
  <results_reference>
    <citation>Baas P, Ardizzoni A, Grossi F, Nackaerts K, Numico G, Van Marck E, van de Vijver M, Monetti F, Smid-Geirnaerdt MJ, van Zandwijk N, Debruyne C, Legrand C, Giaccone G; EORTC Lung Cancer Group. The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). Eur J Cancer. 2003 Feb;39(3):353-7. doi: 10.1016/s0959-8049(02)00668-8.</citation>
    <PMID>12565988</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>January 28, 2000</study_first_submitted>
  <study_first_submitted_qc>April 22, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2004</study_first_posted>
  <last_update_submitted>July 17, 2012</last_update_submitted>
  <last_update_submitted_qc>July 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>localized malignant mesothelioma</keyword>
  <keyword>advanced malignant mesothelioma</keyword>
  <keyword>recurrent malignant mesothelioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltitrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

